TrialCritical care medicine2019

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Richard S Hotchkiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.